Clinical Scorecard: Individuals with Hyperuricemia Tend to Use More Analgesics Compared to Those with Normal Uric Acid Levels—Is Asymptomatic Hyperuricemia Truly Without Symptoms?

At a Glance

Key Highlights

• Hyperuricemia defined as serum uric acid >360 μmol/L; subdivided into renal and metabolic hyperuricemia based on eGFR cutoff of 67 ml/min/1.73 m²
• Higher baseline serum uric acid levels predict increased purchases of NSAIDs, paracetamol, and opioids over 11 years
• Renal function modifies the association between uric acid levels and analgesic use, with metabolic hyperuricemia linked to greater harm

Guideline-Based Recommendations

Diagnosis

• Measure serum uric acid levels to identify hyperuricemia (>360 μmol/L)
• Assess renal function using eGFR (CKD-EPI creatinine-cystatin C equation) to classify hyperuricemia etiology

Management

• Treat gout flares with anti-inflammatory agents: NSAIDs, glucocorticoids, colchicine
• Recognize that analgesic use, including opioids, may be higher in hyperuricemic individuals even without gout attacks
• Consider the chronic nature of gout and recurrent pain management needs

Monitoring & Follow-up

• Monitor analgesic prescriptions objectively via pharmacy records to assess pain management over time
• Evaluate pain intensity and interference using validated tools like SF-36 Bodily Pain section

Risks

• Chronic opioid use is increasing among gout patients and carries risks
• Asymptomatic hyperuricemia is associated with increased all-cause and cause-specific mortality and musculoskeletal pain
• Renal hyperuricemia may be less harmful than metabolic hyperuricemia

Patient & Prescribing Data

Middle-aged to elderly adults with varying serum uric acid levels and renal function status

Higher serum uric acid correlates with increased physician-prescribed analgesic purchases (NSAIDs, paracetamol, opioids) over 11 years; renal function modifies this relationship

Clinical Best Practices

• Use serum uric acid and renal function assessments to stratify hyperuricemia risk and guide management
• Incorporate objective analgesic prescription data to monitor pain and treatment efficacy longitudinally
• Be vigilant for musculoskeletal pain in asymptomatic hyperuricemic patients and consider appropriate analgesic strategies
• Avoid reliance solely on patient-reported pain due to recall bias; supplement with prescription data and validated pain scales

References

• Uric acid metabolism and gout pathophysiology
• Guidelines for gout flare treatment
• Association of hyperuricemia with mortality and comorbidities
• Renal function modifies hyperuricemia outcomes
• GOAL study protocol and population